Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.

医学 托珠单抗 阿巴塔克普 类风湿性关节炎 不利影响 美罗华 内科学 托法替尼 安慰剂 随机对照试验 肿瘤坏死因子抑制剂 塞库金单抗 药理学 阿达木单抗 银屑病性关节炎 淋巴瘤 病理 替代医学
作者
Yoon‐Kyoung Sung,Young Ho Lee
出处
期刊:International Journal of Clinical Pharmacology and Therapeutics [Dustri-Verlag]
卷期号:60 (1): 13-23 被引量:1
标识
DOI:10.5414/cp204036
摘要

This study aimed to evaluate the relative efficacy and safety of biologic agents in patients with rheumatoid arthritis (RA) who show inadequate response to tumor necrosis factor (TNF) inhibitors.A meta-analysis with the Bayesian network, combining direct and indirect randomized controlled trial (RCT) data, was conducted to examine the efficacy and safety of abatacept, rituximab, tocilizumab, sarilumab, sirukumab, and secukinumab in patients with RA who showed inadequate response to TNF inhibitors.8 RCTs enrolling a total of 3,617 patients fulfilled the inclusion criteria. More significant American College of Rheumatology 20% (ACR20), ACR50, and ACR70 responses were obtained using therapies similar to these biologics than with placebo. Ranking probability based on surface under the cumulative ranking curve (SUCRA) indicated that tocilizumab was probably the best treatment for ACR20 response, followed by rituximab, abatacept, sarilumab, sirukumab, secukinumab 150 mg, secukinumab 75 mg, and placebo. Furthermore, identical distribution trends were observed for ACR50 response rates. In comparison, ACR70-based SUCRA rating revealed that rituximab, followed by tocilizumab, abatacept, sirukumab, secukinumab 150 mg, sarilumab, secukinumab 75 mg, and placebo might potentially result in ACR70. There was no significant difference between the number of adverse events and severe adverse events between the treatments.All biologic agents studied were effective in treating patients with TNF inhibitor-refractory RA; however, tocilizumab, rituximab, and abatacept appeared to be more efficient than sarilumab, sirukumab, and secukinumab. There were no differences between the treatments with respect to safety.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
gyusbjshaxb完成签到,获得积分10
1秒前
2秒前
shilong.yang发布了新的文献求助10
2秒前
采集瘤胃液一次完成签到 ,获得积分10
3秒前
ren完成签到,获得积分10
3秒前
韦颖发布了新的文献求助10
3秒前
英俊的铭应助cjt采纳,获得10
4秒前
o30发布了新的文献求助10
4秒前
5秒前
5秒前
大气元彤完成签到,获得积分10
5秒前
5秒前
sos发布了新的文献求助30
5秒前
5秒前
5秒前
guons发布了新的文献求助10
6秒前
LYSM应助LaTeXer采纳,获得10
6秒前
静越发布了新的文献求助10
6秒前
fool完成签到,获得积分10
6秒前
6秒前
badyoungboy完成签到,获得积分10
8秒前
碧蓝紫山完成签到,获得积分20
8秒前
慕青应助俏皮的聪展采纳,获得30
8秒前
Lucas应助小李采纳,获得10
8秒前
cc完成签到,获得积分10
8秒前
Sledge完成签到,获得积分10
9秒前
彭于晏应助桥桥采纳,获得10
9秒前
qindanyan完成签到,获得积分10
9秒前
9秒前
hahasun完成签到,获得积分10
9秒前
10秒前
开心的城完成签到,获得积分10
10秒前
splemeth完成签到,获得积分10
10秒前
爆米花应助无聊的寻梅采纳,获得10
10秒前
轻易发布了新的文献求助10
10秒前
11秒前
科目三应助顺利石头采纳,获得30
11秒前
TYT完成签到,获得积分10
12秒前
偷喝汽水完成签到,获得积分10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969335
求助须知:如何正确求助?哪些是违规求助? 3514162
关于积分的说明 11172430
捐赠科研通 3249456
什么是DOI,文献DOI怎么找? 1794853
邀请新用户注册赠送积分活动 875437
科研通“疑难数据库(出版商)”最低求助积分说明 804809